# methods-audit — claim 0dcfcf95ab706d429bcd1a0d36caa3752f950035307d1f5d8d97bbd875c434b7

Claim: Reported finding from PMID 42340618 (Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial): The combination of palbociclib and tamoxifen delayed deterioration in patients' QoL while they experienced reduced risk for disease progression.
Source: PMID 42340618 (https://pubmed.ncbi.nlm.nih.gov/42340618/)
Checked: 2026-09-23T23:41:51.286Z

## Method
1. Fetched abstract via NCBI efetch.
2. Checklist audit (qwen3:8b, temp 0): design in source: not stated; design matches claim: false; endpoint matches: n/a; population matches: n/a; contradiction: true.
3. Notes: The claim states that 'the combination of palbociclib and tamoxifen delayed deterioration in patients' QoL while they experienced reduced risk for disease progression.' However, the source abstract indicates that 'no significant differences were observed in LSM changes in scores from baseline in global QoL' and 'no clinically meaningful differences between treatment arms were found in the LSM changes in scores from baseline.' Additionally, the median time to deterioration (TTD) in the pain subscale was longer in the palbociclib-tamoxifen arm, but this was not statistically significant (hazard ratio = 0.729 [95% CI: 0.467, 1.138]). Therefore, the claim overstates the findings from the source abstract.
4. Deterministic numeric grounding: missing tokens: none.

## Result
refutes (confidence 7500 bps)

Limitations: abstract-level check only; full text not reviewed.
Source sha256: 229f16ea6c34bf8402ff0cb67a5fb8156b4a400f4f1729a4a57bef9af0140755